Abstract
Sigma-2 receptor plays key roles in promoting tumor cell apoptosis, enhancing efficacy of anti-tumor drugs, blocking signal transduction controlled by Aβ oligomers, regulating Ca2+ homeostasis and protecting nerve cells. Studies indicated that sigma-2 receptor may be closely coupled with ROS, LDL, mTOR, RAS, PLC/PKC, lysosomal autophagy and mitochondrial super oxidative stress. In addition, the high expression of this receptor in proliferating cells and nerve cells indicates that sigma-2 receptor is an ideal molecular target for imaging and therapeutic development for cancer, Alzheimer's disease, schizophrenia and traumatic brain injury. Various sigma-2 agonists have shown promising anticancer activities, while sigma-2 antagonists have displayed neuroprotection and inhibition of Aβ oligomers in the brain of Alzheimer's disease patients. Thus, both sigma-2 agonists and antagonists are potentially useful therapeutics for the management of cancer and neurodegenerative disorders.
Keywords: Sigma-2 receptor, drug target, Aβ protein, biomarker, anticancer, Alzheimer's disease.
Current Medicinal Chemistry
Title:Sigma-2 Receptor as a Potential Drug Target
Volume: 28 Issue: 21
Author(s): Ai-Fang Chen, Wen-Hui Ma, Xiao-Yang Xie and Yun-Sheng Huang*
Affiliation:
- School of Pharmacy, Guangdong Medical University, 1 Xincheng Ave, Songshan Lake Technology Park, Dongguan, Guangdong 523808,China
Keywords: Sigma-2 receptor, drug target, Aβ protein, biomarker, anticancer, Alzheimer's disease.
Abstract: Sigma-2 receptor plays key roles in promoting tumor cell apoptosis, enhancing efficacy of anti-tumor drugs, blocking signal transduction controlled by Aβ oligomers, regulating Ca2+ homeostasis and protecting nerve cells. Studies indicated that sigma-2 receptor may be closely coupled with ROS, LDL, mTOR, RAS, PLC/PKC, lysosomal autophagy and mitochondrial super oxidative stress. In addition, the high expression of this receptor in proliferating cells and nerve cells indicates that sigma-2 receptor is an ideal molecular target for imaging and therapeutic development for cancer, Alzheimer's disease, schizophrenia and traumatic brain injury. Various sigma-2 agonists have shown promising anticancer activities, while sigma-2 antagonists have displayed neuroprotection and inhibition of Aβ oligomers in the brain of Alzheimer's disease patients. Thus, both sigma-2 agonists and antagonists are potentially useful therapeutics for the management of cancer and neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Chen Ai-Fang , Ma Wen-Hui , Xie Xiao-Yang and Huang Yun-Sheng *, Sigma-2 Receptor as a Potential Drug Target, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666200902172615
DOI https://dx.doi.org/10.2174/0929867327666200902172615 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Chemistry-Based Functional Proteomics to Screening for Novel Drug Targets
Combinatorial Chemistry & High Throughput Screening The Heme Oxygenase System: Its Role in Liver Inflammation
Current Drug Targets - Cardiovascular & Hematological Disorders The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators
Medicinal Chemistry NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Withdrawn: Ag/PdTi3O7 Nano Catalyst Promoted for Developing Novel Indole- Naphthyridine Derivatives as Potent Anticancer Agents
Current Organocatalysis Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Current Drug Discovery Technologies Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Treatment Strategies for Fatty Liver Diseases
Reviews on Recent Clinical Trials Recent Trends of Biocompatible and Biodegradable Nanoparticles in Drug Delivery: A Review
Current Medicinal Chemistry Role of microRNAs in Gynecological Pathology
Current Medicinal Chemistry Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Discovery of Novel HDAC Inhibitors by Structure-based Optimization of Cinnamic Hydroxamic Scaffold
Letters in Drug Design & Discovery